Grifols has announced positive results from its phase 2/3 clinical trial evaluating the efficacy and safety of intravenous ...

Grifols has shared positive results from its clinical trial evaluating the efficacy and safety of intravenous immunoglobulin to treat patients with PPS.

Grifols revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential for future profitability. Learn more on GRFS stock here.

Grifols (GRFS) issued a statement to address certain information published in a media outlet on March 8, specifically a front-page article ...

Carson Block of Muddy Waters announced Grifols (GRFS) as a short idea for the Robin Hood contest, according to Bloomberg.Light Up your ...

Activist hedge fund Gotham lambasted healthcare firm Grifols last year. Some of its key criticisms were vindicated. And its ...

Spanish drugmaker Grifols reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7 ...

Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the coming years as it aims to leave behind a tumultuous 2024 when it lost ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the other ...

More than two dozen people rallied on Monday against a for-profit clinic in Whitby that pays people for plasma ...